Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BN201 SAD/MAD Study in Healthy Subjects
NCT03630497Phase 1Completed
- Sponsor
- Accure Therapeutics
- Start
- May 2018
- Primary completion
- Feb 2019
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BN201 in optic neuritis (ON) and multiple sclerosis (MS) (4 arms), sponsored by Accure Therapeutics. Primary endpoints: Adverse Events (AEs) and Serious Adverse Events (SAEs) up to 17 days, Routine Laboratory Safety Screen (Haematology, Biochemistry, Urinalysis) up to 17 days and 8 more. Started May 2018; status: completed.
02
Drugs
BN201
03
Conditions
optic neuritis (ON)multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT03630497.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03630497.